About Tergene Biotech
Tergene Biotech is a Healthcare company based in Hyderabad (India) founded in 2008, and was acquired by Aurobindo Pharma in February 2025. Bio-conjugate technologies for bacterial vaccines and conjugates are developed. Its Indian entity Tergene Biotech Limited reported revenue of βΉ4.46 Cr. Its focus areas include Life Sciences, Immunotherapy, Vaccine and Therapeutic.
Company details
Tergene is developing bio-conjugate platform technologies for novel vaccines and antibody drug conjugates. It has developed technologies for the production of various vaccines and biosimilars such as Acellular Pertussis (ACP) vaccine, Haemophilus influenza type B (HiB) conjugated vaccine, Typhoid Vaccine, Streptokinase, Terinase - a thrombolytic enzyme are some of its developed technologies. The vaccines are currently under advanced stage of development include a multivalent pneumococcal vaccine and Meningococcal vaccine. It also offers a full range of contract research services from bioprocess development to manufacturing to approval of the finished product.
- Headquarters Hyderabad, India
- Stage Acquired
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website tergene.com
- Acquired by Aurobindo Pharma (Feb 2025)
- Legal Name Tergene Biotech Limited
- Date of Incorporation 07 Mar, 2008
- Jurisdiction Hyderabad, Telangana, India
- Annual Revenue₹4.46 Cr
FY 2026 · +4892% YoY
- Net Loss-₹81.8 Lakh
FY 2026 · -18% margin
- EBITDA₹3.86 Cr
FY 2026 · 86% margin
- InvestorsAurobindo Pharma
& 2 more
- Acquired byAurobindo Pharma
(Feb 2025)
Associated legal entities of Tergene Biotech
Tergene Biotech is associated with 2 registered companies on The Company Check; the primary company is Tergene Biotech Limited. Each company page carries the filings, financials, charges and directors of that entity.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2026) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Tergene Biotech Limited CIN U24230TG2008PLC113178 | Active | 07 Mar 2008 | Hyderabad, Telangana | ₹4.5 Cr | 7 | View details | |
| Aurobindo Pharma Ltd Listed CIN L24239TG1986PLC015190 | Active | 26 Dec 1986 | Hyderabad, Telangana | ₹34,147 Cr | 15,925 | 11 | View details |
Funding Insights of Tergene Biotech
- Total Rounds 2
- Investors Count 2
All 2 funding rounds of Tergene Biotech with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2013 | Grant | β | β | ||
| Jun 2012 | Grant | β | β |
3 investors in total: 3 institutional.
Investors in Tergene Biotech
Tergene Biotech has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include Aurobindo Pharma, Department of Biotechnology and BIRAC.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Business incubation services are provided across multiple sectors. | birac.nic.in | Delhi, India | ||
Biotechnology research, guidelines, and funding by the Government of India. | 1986 | dbtindia.gov.in | Delhi, India | |
Generic biocatalytic solutions are provided for pharmaceutical applications. | 1986 | aurobindo.com | Hyderabad, India |
Investor details for Tergene Biotech
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Tergene Biotech Limited (Tergene Biotech)
Tergene Biotech Limited is the primary company behind Tergene Biotech. The boards of the 2 registered companies of Tergene Biotech currently have 14 directors; the longest-serving is Venkata Ramprasad Reddy Penaka, appointed in 1992. 35 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Venkata Ramprasad Reddy Penaka DIN 01284132 | Director | 30 Dec 1992 | 33 yrs 10 mo | Aurobindo Pharma Ltd |
| Nityananda Reddy Kambam DIN 01284195 | Managing Director | 30 Dec 1992 | 33 yrs 10 mo | Aurobindo Pharma Ltd |
| Sarath Chandra Reddy Penaka DIN 01628013 | Director | 27 Sep 2007 | 19 yrs 1 mo | Aurobindo Pharma Ltd |
| Mosuvan Kuppusamy DIN 00066698 | Director | 07 Mar 2008 | 18 yrs 8 mo | Tergene Biotech Limited |
| Kuppusamy Sathyan DIN 01493015 | Director | 07 Mar 2008 | 18 yrs 8 mo | Tergene Biotech Limited |
| Madan Mohan Reddy Mettu DIN 01284266 | Whole-time director | 01 Jan 2013 | 13 yrs 10 mo | Aurobindo Pharma Ltd |
| Sivakumaran Meenakshisunderam DIN 01284320 | Director | 01 Apr 2015 | 11 yrs 7 mo | Tergene Biotech Limited |
| Santhanam Subramanian DIN 03516515 | Director | 26 Aug 2016 | 10 yrs 2 mo | Tergene Biotech Limited |
| Girish Paman Vanvari DIN 07376482 | Director | 05 Nov 2020 | 6 yrs | Aurobindo Pharma Ltd |
| Santanu Mukherjee DIN 07716452 | Director | 09 Feb 2023 | 3 yrs 9 mo | Aurobindo Pharma Ltd |
| Umesh Krishnamoorthy DIN 10195095 | Director | 28 Jun 2023 | 3 yrs 4 mo | Tergene Biotech Limited |
| Satakarni Makkapati DIN 09377266 | Director | 09 Nov 2023 | 3 yrs | Aurobindo Pharma Ltd |
| Mangalam Ramasubramanian Kumar DIN 03628755 | Director | 01 Apr 2024 | 2 yrs 7 mo | Aurobindo Pharma Ltd |
| Punita Kumar Sinha DIN 05229262 | Director | 09 Feb 2026 | 9 mo | Aurobindo Pharma Ltd |
Financials of Tergene Biotech
Figures of Tergene Biotech Limited, the primary company behind Tergene Biotech, for FY 2026. Revenue was ₹4.46 Cr (+4892% year on year). Net loss was -₹81.8 Lakh (-18% margin). EBITDA was ₹3.86 Cr (86% margin). Revenue has grown at a compounded annual rate of -12% over three years and +45% over five years.
- ₹4.46 CrRevenue · FY 2026 · +4892% YoY
- -₹81.8 LakhNet loss · -18% margin
- ₹3.86 CrEBITDA · 86% margin
- ₹47.15 CrPaid-up capital
- -12%Revenue CAGR, 3 years
- +45%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Tergene Biotech Limited are on its company page.
Detailed financial statements for Tergene Biotech
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Tergene Biotech
4 dated milestones of Tergene Biotech across 17 years, from founding to its latest funding, stage changes and deals.
- Founded Tergene Biotech is founded.
- Funding First funding round.
- Funding Latest funding round, Grant,.
- Exit Acquired by Aurobindo Pharma.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Tergene Biotech
Complete news archive for Tergene Biotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Tergene Biotech
Tergene Biotech was founded in 2008 and raised its 1st funding round 4 years after it was founded.
Tergene Biotech is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.
The primary company behind Tergene Biotech, Tergene Biotech Limited, reported revenue of βΉ4.46 Cr for FY 2026, up 4892% year on year.
Tergene is developing bio-conjugate platform technologies for novel vaccines and antibody drug conjugates. It has developed technologies for the production of various vaccines and biosimilars such as Acellular Pertussis (ACP) vaccine, Haemophilus influenza type B (HiB) conjugated vaccine, Typhoid Vaccine, Streptokinase, Terinase - a thrombolytic enzyme are some of its developed technologies. The vaccines are currently under advanced stage of development include a multivalent pneumococcal vaccine and Meningococcal vaccine. It also offers a full range of contract research services from bioprocess development to manufacturing to approval of the finished product.
Tergene Biotech has 3 investors. Key investors include Aurobindo Pharma, Department of Biotechnology, and BIRAC.
Tergene Biotech is associated with 2 legal entities: Tergene Biotech Limited, Aurobindo Pharma Ltd.
Yes. Tergene Biotech was acquired by Aurobindo Pharma in February 2025.
The legal entities of Tergene Biotech currently have 17 directors, including Umesh Krishnamoorthy, Mosuvan Kuppusamy, Sivakumaran Meenakshisunderam and others.

